Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

1.30

Mkt cap

14M

Volume

128K

High

1.33

P/E Ratio

-0.49

52-wk high

7.33

Low

1.28

Div yield

N/A

52-wk low

1.10

EF Hutton analyst Jason Kolbert has reiterated a Buy rating for NRX Pharmaceuticals (NASDAQ:NRXP) and maintained a price target of $31.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 12:51 pm

HOPE Therapeutics and a subsidiary of NRx Pharmaceutical have signed a non-binding letter of intent to acquire interventional psychiatry clinics in Florida. The financial details of the acquisition have not been disclosed.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 12:05 pm

EF Hutton has initiated coverage on NRX Pharmaceuticals with a Buy rating and set a price target of $31, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:31 am

Hope Therapeutics and a subsidiary of NRx Pharmaceuticals have signed a non-binding letter of intent to acquire West Coast Interventional Psychiatric Clinic. The acquisition is expected to be immediately accretive to revenue and EBITDA for both HOPE and NRx. Deal terms were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 10:57 am

NRx Pharmaceuticals (NASDAQ:NRXP) has achieved a key milestone with the 12-month stability of its drug NRX-100, indicating a shelf life of over three years. The company is on track to file a New Drug Application (NDA) in 2024.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:17 am

Ascendiant Capital has maintained a Buy rating on NRX Pharmaceuticals and raised the price target from $43 to $44, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 5:58 pm

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, plans to acquire a network of ketamine treatment clinics with $30 million in financing. The expansion aims to treat conditions like depression and PTSD, projecting $100 million in annual revenue by 2025.

Portfolio Pulse from Rolando García

August 26, 2024 | 10:48 pm

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), has secured non-dilutive debt funding to establish a $100M ketamine clinic network. This expansion aims to provide comprehensive mental health care services for conditions like suicidal depression and PTSD.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 12:02 pm

NRX Pharmaceuticals (NASDAQ:NRXP) reported a Q2 2024 GAAP EPS of $(0.75), missing the analyst consensus estimate of $(0.58) by 29.31%. However, this is an improvement from the $(1.21) per share loss in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:53 pm

NRx Pharmaceuticals has secured up to $16 million in convertible debt financing from an institutional investor. The funds will support the 2024 New Drug Application filing for its two lead products, NRX-100 and NRX-101, and will also be used to retire existing debt from Streeterville Capital.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:36 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.